Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Barry M. Berger"'
Autor:
Galit H. Frydman, DVM, ScD, Barry M. Berger, MD, FCAP, Vadim Kostousov, MD, Karen Bruzdovski, BS, Dimitrios P. Papageorgiou, PhD, Amir Navaei, MD, Shiu-Ki Rocky Hui, MD, Jun Teruya, MD, DSc
Publikováno v:
Critical Care Explorations, Vol 4, Iss 10, p e0776 (2022)
OBJECTIVES:. Bivalirudin, an IV direct thrombin inhibitor, and unfractionated heparin (UFH) are frequently used anticoagulants in the pediatric critical care setting. An accurate, specific, point-of-care test to quantify and detect anticoagulation re
Externí odkaz:
https://doaj.org/article/1cf518411f5845ae8d4a108f8c918588
Autor:
Alicia Gunning, Sunil Kumar, Cassin Kimmel Williams, Barry M. Berger, Stephen P. Naber, Piyush B. Gupta, Catherine Del Vecchio Fitz, Charlotte Kuperwasser
Publikováno v:
Diagnostics, Vol 13, Iss 4, p 725 (2023)
The NavDx® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integr
Externí odkaz:
https://doaj.org/article/4068731a865645a39247783db3a85438
Autor:
Barry M. Berger, Anas Daghestani, Seth Sweetser, Paul J. Limburg, Folasade P. May, Steven H. Itzkowitz, Debbie Jakubowski, Tara N. Marti, Philip T. Lavin, Thomas F. Imperiale
Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported.Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95953a30385c3869212bfea9ba839cc3
https://doi.org/10.1158/1940-6207.c.6547907.v1
https://doi.org/10.1158/1940-6207.c.6547907.v1
Autor:
Barry M. Berger, Anas Daghestani, Seth Sweetser, Paul J. Limburg, Folasade P. May, Steven H. Itzkowitz, Debbie Jakubowski, Tara N. Marti, Philip T. Lavin, Thomas F. Imperiale
Supplemental Table S1: Distribution of colorectal lesions among subjects at baseline (T0) and year 3 (T3). Supplemental Table S2: Study subject accountability in the baseline negative population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491bf66db83c3e8fc84ba36740d632f1
https://doi.org/10.1158/1940-6207.22535663
https://doi.org/10.1158/1940-6207.22535663
Autor:
Barry M. Berger, Anas Daghestani, Seth Sweetser, Paul J. Limburg, Folasade P. May, Steven H. Itzkowitz, Debbie Jakubowski, Tara N. Marti, Philip T. Lavin, Thomas F. Imperiale
This Supplemental Text file provides additional information regarding the clinical procedures and sample processing/lab procedures, as well as an explanation of the sensitivity and robustness analyses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb9a843763715087a92883158a4d6a5
https://doi.org/10.1158/1940-6207.22535660
https://doi.org/10.1158/1940-6207.22535660
Autor:
Paul J. Limburg, Barry M. Berger, Sandra Statz, Emma Kate Duimstra, Bradley Scheu, Steven H. Itzkowitz, John B. Kisiel, Thomas F. Imperiale
High-specificity colorectal cancer screening is desirable to triage patients P = 0.75) or race (P = 0.36) in participants with NAA or negative findings. Sensitivity for APL was 32.7% (CI, 19.9–47.5%), with most APL (83.7%) measuring 10–19 mm and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be959beeb9b5cb38d2d0d37f96c9e26
https://doi.org/10.1158/1940-6207.c.6547337
https://doi.org/10.1158/1940-6207.c.6547337
Autor:
Paul J. Limburg, Barry M. Berger, Sandra Statz, Emma Kate Duimstra, Bradley Scheu, Steven H. Itzkowitz, John B. Kisiel, Thomas F. Imperiale
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ae1c6fdd32cdeba075785aaf8d371a
https://doi.org/10.1158/1940-6207.22533989.v1
https://doi.org/10.1158/1940-6207.22533989.v1
Autor:
Barry M. Berger, Glenn J. Hanna, Marshall R. Posner, Eric M. Genden, Julio Lautersztain, Stephen P. Naber, Catherine Del Vecchio Fitz, Charlotte Kuperwasser
Publikováno v:
Clinical Cancer Research. 28:4292-4301
Purpose: Despite generally favorable outcomes, 15% to 25% of patients with human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) will have recurrence. Current posttreatment surveillance practices rely on physical examination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1279cd98e2ac561bc2aa80de34bf786b
https://doi.org/10.1158/1078-0432.ccr-22-0562
https://doi.org/10.1158/1078-0432.ccr-22-0562
Autor:
Thomas F. Imperiale, Philip T. Lavin, Tara N. Marti, Debbie Jakubowski, Steven H. Itzkowitz, Folasade P. May, Paul J. Limburg, Seth Sweetser, Anas Daghestani, Barry M. Berger
Publikováno v:
Cancer prevention research (Philadelphia, Pa.), vol 16, iss 2
Data supporting the clinical utility of multi-target stool DNA (mt-sDNA) at the guideline-recommended 3-year interval have not been reported. Between April 2015 and July 2016, candidates for colorectal cancer screening whose providers prescribed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdac6a4d8fd1628b2b9179ce35cfc5a5
https://pubmed.ncbi.nlm.nih.gov/36205504
https://pubmed.ncbi.nlm.nih.gov/36205504
Autor:
Christina M. Robinson, Barry M. Berger, William M Hisey, Joseph C. Anderson, Bonny Kneedler, David K Edwards, Lynn F. Butterly
Publikováno v:
Journal of Clinical Gastroenterology. 56:419-425
BACKGROUND The US Preventive Services Task Force (USPSTF) includes multitarget stool DNA (mt-sDNA) testing as a colorectal cancer (CRC) screening option in average-risk individuals, but data on colonoscopy outcomes after positive mt-sDNA tests in com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f289dc6eceb90bec1e3bcfbc0c0ed3bb
https://doi.org/10.1097/mcg.0000000000001554
https://doi.org/10.1097/mcg.0000000000001554